Phase I/prospective randomized phase II trial Of the Safety and Efficacy of tamoxifen in combination with the Isoform selective Pi3K inhibitor GDC-0032 compared with tamoxifen alONe in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment (POSEIDON trial)

Trial Profile

Phase I/prospective randomized phase II trial Of the Safety and Efficacy of tamoxifen in combination with the Isoform selective Pi3K inhibitor GDC-0032 compared with tamoxifen alONe in hormone receptor positive, HER2 negative, metastatic breast cancer patients with prior exposure to endocrine treatment (POSEIDON trial)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2016

At a glance

  • Drugs Taselisib (Primary) ; Tamoxifen
  • Indications Breast cancer; Ovarian cancer; Uterine cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms POSEIDON
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Results (n=32) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 28 Sep 2015 Planned End Date changed from 28 Jun 2019 to 1 Jul 2019 as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top